mRNA Vaccine
Moderna starts human trials of an mRNA-based flu shot
Moderna gave its mRNA-based seasonal flu vaccine to the first set of volunteers in a clinical trial, the pharmaceutical company announced today. The start of the trial marks the next stage of the company’s work on this type of vaccine technology after the overwhelming success of its COVID-19 vaccine, which was built using the same strategy. Before the COVID-19 pandemic, mRNA vaccines were still largely experimental, even as they were heralded as the future of vaccine development. People who get an mRNA vaccine are injected with tiny snippets of genetic material from the target virus. Their cells use that genetic information to build bits of the virus, which the body’s immune system learns to fight against. The high efficacy of the mRNA COVID-19 vaccines made by Moderna and Pfizer / BioNTec...
Interpol raises the alarm over fake coronavirus vaccines
The International Criminal Police Organisation (INTERPOL) has alerted Nigeria, South Africa, the United Kingdom, the United States, and 190 other countries of threat from organised criminal groups during the upcoming COVID-19 vaccination campaigns, including fake vaccines and the theft of supplies. The alert came as the UK yesterday became the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine for widespread use. The need for a vaccine has become more urgent globally and nationally with Nigeria recording over 67,000 COVID-19 infections and over 1,000 associated fatalities, according to the Nigeria Centre for Disease Control. The World Health Organisation (WHO) has so far identified 49 “candidate vaccines” at the stage of clinical trials in humans. Hopes are high ...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
